Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia

Affiliations

• ¹ Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ² Department of Bioinformatics and computational biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ³ Daiichi Sankyo, Co. Ltd., Tokyo, Japan.
• ⁴ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁵ Department of Medicine, Leukemia Service, Center for Hematologic Malignancies, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
• ⁶ Vanderbilt University Cancer Center, Nashville, TN, USA.
• ⁷ Comprehensive Cancer Center, University of Michigan, Grass Lake, MI, USA.
• ⁸ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁹ Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mandreef@mdanderson.org.